Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trehalose
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose
Details : Trehalose is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Muscular Dystrophy, Oculopharyngeal.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
January 13, 2020
Lead Product(s) : Trehalose
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trehalose
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects
Details : Trehalose is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
April 01, 2016
Lead Product(s) : Trehalose
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tehalose
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Continuation Protocol to Protocol BBCO-001
Details : Tehalose is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Muscular Dystrophy, Oculopharyngeal.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 31, 2014
Lead Product(s) : Tehalose
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trehalose API
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cabaletta is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Spinocerebellar Ataxias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2014
Lead Product(s) : Trehalose API
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trehalose API
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cabaletta is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Muscular Dystrophy, Oculopharyngeal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2013
Lead Product(s) : Trehalose API
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
